CG Oncology Stock Earnings Estimates Raised by HC Wainwright

CG Oncology, Inc. (NASDAQ:CGON – Free Report) – Research analysts at HC Wainwright raised their FY2028 earnings estimates for shares of CG Oncology in a note issued to investors on Tuesday, November 17th. HC Wainwright analyst A. Maldonado now anticipates that the company will earn ($1.01) per share for the year, up from their prior estimate of ($1.33). HC Wainwright currently has a “Buy” rating and a $115.00 target price on the stock. The consensus estimate for CG Oncology’s current full-year earnings is ($2.97) per share. HC Wainwright also issued estimates for CG Oncology’s FY2029 earnings at $3.01 EPS and FY2030 earnings at $5.96 EPS.

A number of other equities analysts have also issued reports on the company. Morgan Stanley increased their price target on CG Oncology from $102.00 to $117.00 and gave the company an “overweight” rating in a research note on Wednesday. Wedbush lifted their price target on CG Oncology from $84.00 to $91.00 and gave the company an “outperform” rating in a research report on Tuesday. JPMorgan Chase & Co. boosted their price objective on CG Oncology from $96.00 to $113.00 and gave the stock an “overweight” rating in a research note on Tuesday. Guggenheim upped their price objective on CG Oncology from $89.00 to $120.00 and gave the company a “buy” rating in a report on Thursday. Finally, Weiss Ratings restated a “sell (d-)” rating on shares of CG Oncology in a report on Thursday, October 15th. Eight research analysts have rated the stock with a Buy rating, two have given a Hold rating and one has issued a Sell rating to the company. According to MarketBeat, CG Oncology currently has a consensus rating of “Moderate Buy” and a consensus target price of $102.22.

Check Out Our Latest Analysis on CGON

CG Oncology Price Performance

Shares of NASDAQ:CGON opened at $79.47 on Thursday. CG Oncology has a 12 month low of $37.01 and a 12 month high of $93.95. The stock has a market cap of $7.10 billion, a price-to-earnings ratio of -28.79 and a beta of 0.35. The stock’s 50 day moving average price is $68.85 and its 200 day moving average price is $67.24.

CG Oncology (NASDAQ:CGON – Get Free Report) last posted its quarterly earnings data on Friday, November 6th. The company reported ($0.64) EPS for the quarter, beating analysts’ consensus estimates of ($0.83) by $0.19. CG Oncology had a negative net margin of 3,851.09% and a negative return on equity of 24.58%. The business had revenue of $1.60 million for the quarter, compared to analyst estimates of $0.55 million.

Insider Transactions at CG Oncology

In other news, Director Leonard E. Post sold 1,000 shares of CG Oncology stock in a transaction that occurred on Monday, November 16th. The shares were sold at an average price of $92.00, for a total value of $92,000.00. Following the transaction, the director owned 1,000 shares of the company’s stock, valued at $92,000. The trade was a 50.00% decrease in their position. The sale was disclosed in a document filed with the SEC, which is accessible through this link. Also, insider Isabel Kalofonos bought 3,751 shares of the company’s stock in a transaction that occurred on Wednesday, November 18th. The stock was acquired at an average price of $79.75 per share, for a total transaction of $299,142.25. Following the completion of the acquisition, the insider directly owned 3,751 shares in the company, valued at approximately $299,142.25. This represents a ∞ increase in their ownership of the stock. Additional details regarding this purchase are available in the official SEC disclosure. Insiders have sold 3,000 shares of company stock valued at $227,040 in the last quarter. Insiders own 4.80% of the company’s stock.

Institutional Inflows and Outflows

Hedge funds have recently added to or reduced their stakes in the business. Fiduciary Financial Advisors acquired a new position in shares of CG Oncology in the 2nd quarter valued at $28,000. Manchester Capital Management LLC increased its stake in CG Oncology by 2,895.5% in the 3rd quarter. Manchester Capital Management LLC now owns 659 shares of the company’s stock worth $47,000 after purchasing an additional 637 shares in the last quarter. Covestor Ltd increased its stake in CG Oncology by 72.6% in the 3rd quarter. Covestor Ltd now owns 770 shares of the company’s stock worth $55,000 after purchasing an additional 324 shares in the last quarter. GAMMA Investing LLC raised its holdings in CG Oncology by 47.9% during the 3rd quarter. GAMMA Investing LLC now owns 1,081 shares of the company’s stock worth $77,000 after buying an additional 350 shares during the period. Finally, Fifth Third Bancorp acquired a new stake in CG Oncology during the 1st quarter worth about $74,000. Institutional investors and hedge funds own 26.56% of the company’s stock.

Key Stories Impacting CG Oncology

Investors following CGON have been watching these stories:

  • Positive Sentiment: Analysts raised targets and forecasts. Guggenheim lifted its price target to $120 from $89 and kept a Buy rating. HC Wainwright raised its longer-term earnings estimates and maintains a $115 target and Buy rating. Morgan Stanley also reportedly sees potential for strong appreciation. Guggenheim analyst coverage Morgan Stanley forecast
  • Positive Sentiment: Executives bought shares. CEO Arthur Kuan and another executive reportedly purchased about $2.7 million of CGON stock after the CEO described the company’s trial results as a “defining milestone.” A separate filing showed insider Isabel Kalofonos bought 3,751 shares for about $299,000. Such purchases may signal management confidence, though they do not guarantee future performance. Report on trial results and insider purchases
  • Neutral Sentiment: Clinical and financial uncertainty remains. CG Oncology is a clinical-stage biotech, and the cited earnings projections are several years out. Trial follow-up and regulatory progress remain important to the investment case.

CG Oncology Company Profile

(Get Free Report)

CG Oncology is a clinical-stage biotechnology company focused on developing treatments for bladder cancer. Based in Irvine, California, the company’s research centers on therapies delivered directly into the bladder. Its lead investigational therapy, cretostimogene grenadenorepvec (formerly CG0070), is an oncolytic immunotherapy being developed for non-muscle-invasive bladder cancer, including disease that has not responded to Bacillus Calmette-Guérin (BCG) treatment. The modified virus is designed to target cancer cells and stimulate an immune response.

Read More

Earnings History and Estimates for CG Oncology (NASDAQ:CGON)

Receive News & Ratings for CG Oncology Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for CG Oncology and related companies with MarketBeat.com's FREE daily email newsletter.